CLT-005

CLT-005 is a small molecule compound with potent anti-inflammatory and anti-angiogenic activity.  CLT-005 inhibits modulations in cellular transcription that occur in response to inflammatory or angiogenic factors.

CLT-005 reduces expression levels of several inflammatory and pro-angiogenic genes following intranitreal administration

Two weeks following induction of diabetes with STZ, rats received an intravitreal injection of 50 ng or 5 µg of CLT-005 in one eye, and the vehicle (DMSO) alone in the contralateral eye. As a control, non-diabetic rats of the same age also received and intravitreal injection of 5 µg of CLT-005 in one eye and the vehicle (DMSO) alone in the contralateral eye. injection of 5 µL of 10 mM or 30 mM CLT-005 in one eye and vehicle in the contralateral eye. The retinal levels of TNF-alpha, MCP-1, ICAM-1, LRP-5 and LRP-6 were quantified with qRT-PCR 24 hrs post-administration. For all genes examined, diabetes induced expression of these genes, which was restored to baseline levels upon treatment with CLT-005. (One-way ANOVA with Tukey’s multiple comparison post-hoc test, * p < 0.05, ** p < 0.01, n=8).